Category: Federal Forum Posters
Purpose: The objective of this quality improvement/resident project is to evaluate clinical outcomes associated with atezolizumab, nivolumab, and pembrolizumab in the treatment of Veterans with metastatic NSCLC within Veterans Integrated Service Network 21 (VISN 21). The goal of the project is to use our findings to shape future decisions in the management of NSCLC in VISN 21 and possibly identify positive predictive factors for patient response. Results will be shared with Oncology providers and the VISN 21 Oncology Task Force. We hope to identify future strategies to improve treatment outcomes and appropriate drug therapy selection for Veterans.
Methods: This resident project is endorsed by VISN 21 Oncology task force and was reviewed by the Institutional Review Board and determined to be a quality improvement project. This is a retrospective review of patients that have already received treatment. All Veterans who received therapy with atezolizumab, nivolumab, and pembrolizumab for the treatment of metastatic NSCLC will be identified through data from the Veterans Affairs Integrated Service Network data warehouse and electronic medical records. Information to be collected will include patient demographic data, prior oncologic therapies, IV infusion data, and documented adverse events. Data will be collected, de-identified according to HIPAA standards, reported in aggregate, and stored behind the VA system firewall on a secure server. For each medication, treatment course information and efficacy outcomes will be collected including length of therapy, overall survival, progression-free survival, overall response rate and median duration of response.
Results: Not applicable
Conclusion: Not applicable
Kjersti Rich– PGY2 Pharmacy Outcomes & Healthcare Analytics Resident, VA Sierra Pacific Network PBM (VISN21), Reno, NV